Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2022-04-21 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于2021年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2021 annual profit distribution plan of a company. It includes details about the audited net profit, the proposed cash dividend per share, and the approval process involving the board and supervisory committee. It explicitly states that the profit distribution plan needs to be approved by the shareholders' meeting. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. The length is short (1925 characters), and the content is an announcement of a profit distribution plan rather than a full annual report or interim report. Therefore, it fits best under the category of Notice of Dividend Amount (DIV).
2022-04-21 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2021 by 葵花药业集团股份有限公司. It contains detailed descriptions of the company's internal control environment, risk assessment, control activities, and evaluation conclusions regarding internal control effectiveness as of December 31, 2021. The content focuses on internal control evaluation rather than full financial statements or audit opinions. It is not an annual report (10-K), audit report (AR), or interim report (IR). It is a standalone report on internal control self-assessment, which aligns with the category of Audit Report / Information (AR), as it relates to internal control evaluation and compliance with regulatory internal control standards. The document length is sufficient and contains substantive content, not just an announcement or certification. Therefore, the best fitting classification is AR (Audit Report / Information). FY 2021
2022-04-21 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 4th Board of Directors of a company, including approval of the 2021 annual report, financial statements, profit distribution plan, internal control report, and other governance matters. It includes voting results and mentions that these matters will be submitted to the 2021 Annual General Meeting for approval. The document is not the annual report itself but a board meeting resolution announcement related to governance and management decisions. It does not contain the full financial report or detailed financial statements but rather the board's decisions and approvals. Therefore, it fits best under Board/Management Information (MANG). The document length is 4203 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2022-04-21 Chinese
独立董事述职报告（李华杰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2021" for a company, detailing the independent director's attendance at board and committee meetings, opinions expressed on various company matters, and activities performed during the year. It is a narrative report on the director's duties and oversight rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. It is a governance-related report focusing on the director's role and compliance with governance standards. Therefore, it fits best under Board/Management Information (MANG), which includes announcements or reports related to board members' activities and governance roles.
2022-04-21 Chinese
独立董事述职报告（崔丽晶）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2021" from a company, detailing the independent director's attendance at board and committee meetings, opinions expressed on various company matters, and activities related to governance and oversight during the fiscal year 2021. It includes detailed descriptions of the director's duties, meeting participation, and governance-related opinions, but does not contain financial statements or audit results. This type of document is a report on board/management activities and governance oversight rather than a full annual report, audit report, or financial statement. It is not a simple announcement or certification but a substantive report on management/board activities. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 2294 characters, which is consistent with a detailed report but not a full annual report or audit report.
2022-04-21 Chinese
关于2022年度预计担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the expected guarantee amount for the year 2022. It details the guarantee limits, the companies involved, financial data of subsidiaries, board and independent directors' opinions, and legal authorization for signing guarantee-related documents. The document is relatively short (3472 characters) and focuses on a specific financial guarantee matter rather than presenting comprehensive financial statements or a full report. It does not contain quarterly or annual financial results, nor is it a transcript, audit report, or management discussion. It is a regulatory announcement about a financing-related guarantee activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-04-21 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.